Nplus1 Singer Capital Markets Ltd Form 8.5 (EPT/RI) Bioquell Plc (2744N)
16 Janeiro 2019 - 8:46AM
UK Regulatory
TIDMBQE
RNS Number : 2744N
Nplus1 Singer Capital Markets Ltd
16 January 2019
FORM 8.5 (EPT/RI)
PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH
RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING
CAPACITY
Rule 8.5 of the Takeover Code (the "Code")
1. KEY INFORMATION
(a) Name of exempt principal trader: Nplus1 Singer Capital Markets Limited
(b) Name of offeror/offeree in relation to whose relevant securities this Bioquell Plc
form relates:
Use a separate form for each offeror/offeree
--------------------------------------
(c) Name of the party to the offer with which exempt principal trader is Bioquell Plc
connected:
--------------------------------------
(d) Date dealing undertaken: 15 January 2019
--------------------------------------
(e) In addition to the company in 1(b) above, is the exempt principal trader NO
making disclosures
in respect of any other party to this offer? If YES, specify which:
If it is a cash offer or possible cash offer, state "N/A"
--------------------------------------
2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER
Where there have been dealings in more than one class of
relevant securities of the offeror or offeree named in 1(b), copy
table 2(a), (b), (c) or (d) (as appropriate) for each additional
class of relevant security dealt in.
The currency of all prices and other monetary amounts should be
stated.
(a) Purchases and sales
Class of relevant Purchases/ sales Total number of Highest price per Lowest price per unit
security securities unit paid/received paid/received
Ord 10p Purchase 500 581.1p 581.1p
------------------ ----------------------- ---------------------- -----------------------
(b) Cash-settled derivative transactions
Class of relevant Product description Nature of dealing Number of reference Price per unit
security e.g. CFD e.g. opening/closing a securities
long/short position,
increasing/reducing a
long/short position
(c) Stock-settled derivative transactions (including options)
(i) Writing, selling, purchasing or varying
Class of Product Writing, Number of Exercise Type Expiry date Option money
relevant description purchasing, securities price per e.g. paid/
security e.g. call selling, to which unit American, received per
option varying etc. option European unit
relates etc.
(ii) Exercise
Class of relevant Product description Exercising/ exercised Number of securities Exercise price per
security e.g. call option against unit
(d) Other dealings (including subscribing for new securities)
Class of relevant security Nature of dealing Details Price per unit (if applicable)
e.g. subscription, conversion
3. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or any agreement or understanding, formal
or informal, relating to relevant securities which may be an inducement to deal or refrain
from dealing entered into by the exempt principal trader making the disclosure and any party
to the offer or any person acting in concert with a party to the offer:
Irrevocable commitments and letters of intent should not be included. If there are no such
agreements, arrangements or understandings, state "none"
(b) Agreements, arrangements or understandings relating to options or derivatives
Details of any agreement, arrangement or understanding, formal or informal, between the exempt
principal trader making the disclosure and any other person relating to:
(i) the voting rights of any relevant securities under any option; or
(ii) the voting rights or future acquisition or disposal of any relevant securities to which
any derivative is referenced:
If there are no such agreements, arrangements or understandings, state "none"
Date of disclosure: 16 January 2019
Contact name: Damian Fernandez
-----------------
Telephone number: 020 7496 3094
-----------------
Public disclosures under Rule 8 of the Code must be made to a
Regulatory Information Service and must also be emailed to the
Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market
Surveillance Unit is available for consultation in relation to the
Code's dealing disclosure requirements on +44 (0)20 7638 0129.
The Code can be viewed on the Panel's website at
www.thetakeoverpanel.org.uk.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
FERBFMMTMBIBBAL
(END) Dow Jones Newswires
January 16, 2019 05:46 ET (10:46 GMT)
Bioquell (LSE:BQE)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Bioquell (LSE:BQE)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024
